CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions

Journal of Immunology

Volumn 177, Issue 5, 2006, Pages 3055-3062

  Lambe, Teresa ^a   Leung, Janson C H ^a   Bouriez Jones, Tiphaine ^a   Silver, Karlee ^a   Makinen, Kimmo ^b   Crockford, Tanya L ^a   Ferry, Helen ^a   Forrester, John V ^b   Cornell, Richard J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL ANTIGEN; FAS ANTIGEN; FAS LIGAND; LYSOZYME; MELANOCYTE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; THYMUS; VITILIGO; VITILIGO VULGARIS; VOGT KOYANAGI SYNDROME;

EID: 33747798344     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.5.3055     Document Type: Article

References (79)

1. Lin, M., Z. Liu, B. A. Drolet, and L. A. Diaz. 1998. Cutaneous autoimmune diseases. In The Autoimmune Diseases, 3rd Ed. N. R. Rose, and I. R. Mackay, eds. Academic, San Diego, CA, pp. 545-571.
2. Lerner, A. B. 1959. Vitiligo. J. Invest. Dermatol. 32: 285-310.
3. Handa, S., and I. Kaur. 1999. Vitiligo: clinical findings in 1436 patients. J. Dermatol. 26: 653-657.
4. Ongenae, K., N. Van Geel, and J. M. Naeyaert. 2003. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16: 90-100.
5. Das, P. K., R. M. van den Wijngaard, A. Wankowicz-Kalinska, and I. C. Le Poole. 2001. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol. 22: 130-136.
6. Le Poole, I. C., R. M. van den Wijngaard, W. Westerhof, and P. K. Das. 1996. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148: 1219-1228.
7. Palermo, B., R. Campanelli, S. Garbelli, S. Mantovani, E. Lantelme, V. Brazzelli. M. Ardigo, G. Borroni, M. Martinetti, C. Badulli, et al. 2001. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J. Invest. Dermatol. 117: 326-332.
8. Wankowicz-Kalinska, A., C. Le Poole, R. van den Wijngaard, W. J. Storkus, and P. K. Das. 2003. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res. 16: 254-260.
9. Ahonen, P., S. Myllarniemi, I. Sipila, and J. Perheentupa. 1990. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 322: 1829-1836.
10. Scott, H. S., M. Heino, P. Peterson, L. Mittaz, M. D. Lalioti, C. Betterle, A. Cohen, M. Seri, M. Lerone, G. Romeo, et al. 1998. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol. Endocrinol. 12: 1112-1119.
11. Takase, H., C.-R. Yu, R. M. Mahdi, D. C. Douek, G. B. DiRusso, F. M. Midgley, R. Dogra, G. Allende, E. Rosenkranz, A. Pugliese, et al. 2005. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int. Immunol. 17: 1131-1140.
12. + T cells and local inflammation: implications for the pathophysiology of vitiligo. J. Invest. Dermatol. 124: 144-150.
13. Alferink, J., A. Tafuri, D. Vestweber, R. Hallmann, G. J. Hämmerling, and B. Arnold. 1998. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 282: 1338-1341.
14. + T cells. J. Exp. Med. 198: 569-580.
15. Colella, T. A., T. N. J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk. C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191: 1221-1232.
16. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y.-X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
17. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
18. Engelhard, V. H., T. N. Bullock, T. A. Colella, S. L. Sheasley, and D. W. Mullins. 2002. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188: 136-146.
19. Phan, G. Q., P. Attia, S. M. Steinberg, D. E. White, and S. A. Rosenberg. 2001. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19: 3477-3482.
20. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
21. Chambers, C. A., M. S. Kuhns, J. G. Egen, and J. P. Allison. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19: 565-594.
22. van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366.
23. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
24. Ferry, H., M. Jones, D. J. Vaux, I. S. Roberts, and R. J. Cornall. 2003. The cellular location of self-antigen determines the positive and negative selection of autoreactive B cells. J. Exp. Med. 198: 1415-1425.
25. Zhao, S., and P. A. Overbeek. 1999. Tyrosinase-related protein 2 promoter targets transgene expression to ocular and neural crest-derived tissues. Dev. Biol. 216: 154-163.
26. + T cells. J. Exp. Med. 179: 1539-1549.
27. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
28. Jiang, H. R., L. Lumsden, and J. V. Forrester. 1999. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest. Ophthalmol. Vis. Sci. 40: 3177-3185.
29. Goodnow, C. C., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael, et al. 1988. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334: 676-682.
30. Van Parijs, L., D. A. Peterson, and A. K. Abbas. 1998. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8: 265-274.
31. Townsend, S. E., and C. C. Goodnow. 1998. Abortive proliferation of rare T cells induced by direct or indirect antigen presentation by rare B cells in vivo. J. Exp. Med. 187: 1611-1621.
32. Akkaraju, S., W. Y. Ho, D. Leong, K. Canaan, M. M. Davis, and C. C. Goodnow. 1997. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows nondestructive thyroiditis or insulitis. Immunity 7: 255-271.
33. Bowne, W. B., R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis, and A. N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190: 1717-1722.
34. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
35. Turk, M. J., J. D. Wolchok, J. A. Guevara-Patino, S. M. Goldberg, and A. N. Houghton. 2002. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188: 122-135.
36. Lane, C., J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan. 2004. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 64: 1509-1514.
37. Allen, P. M., G. R. Matsueda, R. J. Evans, J. B. Dunbar, Jr., G. R. Marshall, and E. R. Unanue. 1987. Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature 327: 713-715.
38. Yamaki, K., K. Gocho, K. Hayakawa, I. Kondo, and S. Sakuragi. 2000. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J. Immunol. 165: 7323-7329.
39. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2: 301-306.
40. Schwartz, R. H. 2003. T cell anergy. Annu. Rev. Immunol. 21: 305-334.
41. Lohr, J., B. Knoechel, V. Nagabhushanam, and A. K. Abbas. 2005. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol. Rev. 204: 116-127.
42. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16: 201-223.
43. Liston, A., S. Lesage, J. Wilson, L. Peltonen, and C. C. Goodnow. 2003. Aire regulates negative selection of organ-specific T cells. Nat. Immunol. 4: 350-354.
44. + T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo. Eur. J. Cell Biol. 83: 797-803.
45. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
46. Ohashi, P. S., and A. L. DeFranco. 2002. Making and breaking tolerance. Curr. Opin. Immunol. 14: 744-759.
47. + CTL that utilizes a perform- rather than a Fas ligand-dependent cytotoxic mechanism. J. Immunol. 156: 153-159.
48. Trapani, J. A. 1998. Dual mechanisms of apoptosis induction by cytotoxic lymphocytes. Int. Rev. Cytol. 182: 111-192.
49. Castro, J. E., J. A. Listman, B. A. Jacobson, Y. Wang, P. A. Lopez, S. Ju, P. W. Finn, and D. L. Perkins. 1996. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5: 617-627.
50. Keegan, B. M., and J. H. Noseworthy. 2002. Multiple Sclerosis. Annu. Rev. Med. 53: 285-302.
51. Egwuagu, C. E., P. Charukamnoetkanok, and I. Gery. 1997. Thymic expression of autoantigens correlates with resistance to autoimmune disease. J. Immunol. 159: 3109-3112.
52. Liston, A., D. H. Gray, S. Lesage, A. L. Fletcher, J. Wilson, K. E. Webster, H. S. Scott, R. L. Boyd, L. Peltonen, and C. C. Goodnow. 2004. Gene dosage: limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J. Exp. Med. 200: 1015-1026.
53. Lesage, S., S. B. Hartley, S. Akkaraju, J. Wilson, M. Townsend, and C. C. Goodnow. 2002. Failure to censor forbidden clones of CD4 T cells in autoimmune diabetes. J. Exp. Med. 196: 1175-1188.
54. + of T-helper cells in non-segmental vitiligo. J. Dermatol. 29: 68-73.
55. Heath, W. R., G. T. Belz, G. M. N. Behrens, C. M. Smith, S. P. Forehan, I. A. Parish, G. M. Davey, N. S. Wilson, F. R. Carbone, and J. A. Villadangos. 2004. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199: 9-26.
56. Turley, S., L. Poirot, M. Hattori, C. Benoist, and D. Mathis. 2003. Physiological β cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J. Exp. Med. 198: 1527-1537.
57. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196: 1099-1104.
58. + dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106: 201-206.
59. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol. 161: 1220-1230.
60. Le Poole, I. C., A. Wankowicz-Kalinska, R. M. van den Wijngaard, B. J. Nickoloff, and P. K. Das. 2004. Autoimmune aspects of depigmentation in vitiligo. J. Investig. Dermatol. Symp. Proc. 9: 68-72.
61. + T cells to type-1 -like is associated with melanocyte loss in human vitiligo. Lab. Invest. 83: 683-695.
62. Sulaimon, S. S., and B. E. Kitchell. 2003. The biology of melanocytes. Vet. Dermatol. 14: 57-65.
63. Jenkins, M. K., A. Khoruts, E. Ingulli, D. L. Mueller, S. J. McSorley, R. L. Reinhardt, A. Itano, and K. A. Pape. 2001. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19: 23-45.
64. Reinhardt, R. L., D. C. Bullard, C. T. Weaver, and M. K. Jenkins. 2003. Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J. Exp. Med. 197: 751-762.
65. Anderson, R. P., D. A. van Heel, J. A. Tye-Din, M. Barnardo, M. Salio, D. P. Jewell, and A. V. S. Hill. 2005. T cells in peripheral blood after gluten challenge in coeliac disease. Gut 54: 1217-1223.
66. Ogg, G. S., P. Rod Dunbar, P. Romero, J.-L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188: 1203-1208.
67. Badri, A. M., P. M. Todd, J. J. Garioch, J. E. Gudgeon, D. G. Stewart, and R. B. Goudie. 1993. An immunohistological study of cutaneous lymphocytes in vitiligo. J. Pathol. 170: 149-155.
68. Pape, K. A., V. Kouskoff, D. Nemazee, H. L. Tang, J. G. Cyster, L. E. Tze, K. L. Hippen, T. W. Behrens, and M. K. Jenkins. 2003. Visualization of the genesis and fate of isotype-switched B cells during a primary immune response. J. Exp. Med. 197: 1677-1687.
69. + T cells. Nature 376: 181-184.
70. Hahn, S., R. Gehri, and P. Erb. 1995. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 146: 57-79.
71. Le Poole, I. C., T. Mutis, R. M. van den Wijngaard, W. Westerhof, T. Ottenhoff, R. R. de Vries, and P. K. Das. 1993. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J. Immunol. 151: 7284-7292.
72. al Badri, A. M., A. K. Foulis, P. M. Todd, J. J. Gariouch, J. E. Gudgeon, D. G. Stewart, J. A. Gracie, and R. B. Goudie. 1993. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J. Pathol. 169: 203-206.
73. Bullani, R. R., P. Wehrli, I. Viard-Leveugle, D. Rimoldi, J.-C. Cerottini, J.-H. Saurat, J. Tschopp, and L. E. French. 2002. Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res. 12: 263-270.
74. Siegel, R. M., F. K. Chan, H. J. Chun, and M. J. Lenardo. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1: 469-474.
75. Sfondrini, L., D. Morelli, A. Bodini, M. I. Colnaghi, S. Menard, and A. Balsari. 1999. High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma. Int. J. Cancer 83: 107-112.
76. Ramirez-Montagut, T., M. J. Turk, J. D. Wolchok, J. A. Guevara-Patino, and A. N. Houghton. 2003. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22: 3180-3187.
77. Loftus, D. J., C. Castelli, T. M. Clay, P. Squarcina, F. M. Marincola, M. I. Nishimura, G. Parmiani, E. Appella, and L. Rivoltini. 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184: 647-657.
78. Gray, D., K. Siepmann, and G. Wohlleben. 1994. CD40 ligation in B cell activation, isotype switching and memory development. Semin. Immunol. 6: 303-310.
79. + T-cell responses. Curr. Opin. Immunol. 16: 259-263.